Indonesia, through state-owned vaccine manufacturer PT Bio Farma (Persero), has long played a pivotal role in global vaccine access and public health. Since becoming one of the founding members of the Developing Countries Vaccine Manufacturers’ Network (DCVMN) in 2000, Bio Farma has advanced efforts in vaccine self-sufficiency and collaboration among developing countries. By hosting the DCVMN’s second Annual General Meeting in 2001 in Bandung and later holding the chairmanship for the 2023-2025 term, Indonesia has underscored its commitment to global health innovation, equitable access, and strengthening vaccine capacity in lower- and middle-income countries.
Bio Farma’s impact reaches far beyond representation. For example, in 2004 it participated in a technology-transfer initiative to expand access to the pentavalent (DPT-HepB-Hib) vaccine through DCVMN partnerships, illustrating its technical and practical contributions. In a landmark achievement, its nOPV2 vaccine became the first from a developing-country manufacturer to receive an Emergency Use Listing from the World Health Organization (WHO) in 2020, demonstrating the company’s ability to meet international standards of safety, quality, and efficacy. With a production capacity of over 3.5 billion doses per year and supply relationships in more than 150 countries, Bio Farma continues to shape a more resilient and equitable global vaccine ecosystem.
